Business Context and Reporting Period
This Form 8-K is filed by Bond Laboratories, Inc. (not Fitlife Brands, Inc.) for the reporting period ending August 28, 2009. The company is a Nevada corporation headquartered in Omaha, NE. The filing primarily reports on the completion of unregistered private equity financing transactions.
Key Financial Metrics
The filing details capital raised through two distinct private placements:
- Primary Financing: Completed August 28, 2009, with aggregate proceeds of $456,250.
- Follow-on Offering: Closed subsequent to the primary financing with gross proceeds of $68,250.
- Total Capital Raised: $524,500.
- Equity Issued: 2,417,750 common shares (2,281,250 in primary; 136,500 in follow-on).
- Warrants Issued: 2,417,750 warrants total (2,281,250 Series A; 136,500 Series B).
Note: The filing does not provide data on revenue, profit, operating cash flow, margins, existing debt, or liquidity ratios.
Material Changes
The material change reported is the significant increase in outstanding equity and potential dilution resulting from the issuance of new shares and warrants. The company executed these transactions under exemptions provided by Sections 4(2) and 4(6) of the Securities Act of 1933 and Rule 506 of Regulation D.
Terms, Outlook, and Risks
Financing Terms:
- Series A Warrants: 3-year term, exercise price of $0.35 per share. No anti-dilution or pre-emptive rights.
- Series B Warrants: 3-year term, exercise price of $0.75 per share. No anti-dilution or pre-emptive rights.
Outlook and Risks: The filing does not contain management commentary on future business outlook, specific risks, or contingencies beyond the standard disclosure of the unregistered sale of securities.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the use of proceeds from the $524,500 raised (not specified in this filing).
- Review the company's current cash position to determine if this capital resolves immediate liquidity needs.
- Check for any subsequent filings regarding the exercise of the Series A and Series B warrants.